Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis 2. Immunology: $10,293M in FY2025, up 10.8% from a year earlier.
Latest, FY2025
10,293
Period ended Dec 31, 2025
Change on a year earlier
+10.8%
9,293 in FY2024
History
4 years
Since FY2022
Sources
3
Documents cited below
Where the FY2025 figure comes from
“|| Total immunology | 10 293 | 9 293 | 11 | 10”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K (Net sales by therapeutic area) & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | 2. Immunology ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10,293 | +10.8% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 9,293 | +19.2% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 7,798 | +7.0% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 7,287 | – | Novartis Form 6-K (0001370368-24-000007) ↗ |
Breakdown
What makes up 2. Immunology
- Therapeutic Area Revenue Growth at Constant Currencies (% cc)10.0% · FY2025
- Therapeutic Area Revenue Growth in USD (% USD)11.0% · FY2025
- Cosentyx (secukinumab — psoriasis, psoriatic arthritis, ankylosing spondylitis & HS)6,668 · FY2025
- Ilaris (canakinumab — autoinflammatory periodic fever syndromes & Still's disease)1,883 · FY2025
- Xolair (omalizumab — allergic asthma, chronic spontaneous urticaria CSU & food allergies, ex-US + co-promotion)1,723 · FY2025
- Rhapsido (remibrutinib — oral BTK inhibitor for chronic spontaneous urticaria CSU, launch Q4 2025)19 · FY2025
Cite this data
StockData. (2026). Novartis 2. Immunology ($M), annual FY2022–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/ta-immunology
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.